Literature DB >> 6833439

High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine.

P O Okonkwo, I W Reimann, R Woestenborghs, U Klotz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6833439     DOI: 10.1016/s0378-4347(00)86149-6

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  15 in total

Review 1.  Clinical pharmacokinetics of ketanserin.

Authors:  B Persson; J Heykants; T Hedner
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Effect of the acute sublingual administration of ketanserin in hypertensive patients.

Authors:  G Aliberti; E D'Erasmo; C M Oddo; E Vecci
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

4.  Bioavailability and pharmacokinetics of ketanserin in elderly subjects.

Authors:  M Kurowski
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.

Authors:  J Heykants; A Van Peer; R Woestenborghs; S Gould; J Mills
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol.

Authors:  A Van Peer; R Woestenborghs; L Embrechts; J Heykants
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Pharmacokinetics of ketanserin in man.

Authors:  I W Reimann; P O Okonkwo; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Pharmacokinetics of ketanserin in patients with essential hypertension.

Authors:  B Persson; A Pettersson; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?

Authors:  S E Gould; J H Silas; J Hosie
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

10.  Interaction of ketanserin and its metabolite ketanserinol with 5HT2 receptors in pulmonary and coronary arteries of calf.

Authors:  M Frenken; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.